{"id":506,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2022-08-19","marketCap":4.554689884185791,"name":"PaxMedica Inc","phone":"19149872876.0","outstanding":1.0099999904632568,"symbol":"PXMD","website":"https://www.paxmedica.com/","industry":"Pharmaceuticals"},"price":6.275,"year":2023,"month":11,"day":8,"weekday":"Wednesday","title":"Corporate Governance Practices of PaxMedica Inc Stock","date":"2023-11-08","url":"/posts/2023/11/08/PXMD","content":[{"section":"Board Composition","text":"PaxMedica Inc has a diverse board composition consisting of nine members. The board includes individuals with backgrounds in healthcare, finance, and technology, bringing a variety of expertise to the company. The board is comprised of both independent directors and executive directors, ensuring a balance between objective oversight and internal management representation. The board also has a separate chairman who is responsible for leading board meetings and ensuring effective corporate governance practices."},{"section":"Executive Compensation","text":"PaxMedica Inc follows a performance-based executive compensation policy, linking executive pay to the company's financial and strategic performance. The compensation package includes a combination of base salary, annual incentives, and long-term incentives such as stock options and restricted stock units. The board's compensation committee regularly evaluates the performance of executives and determines appropriate compensation levels based on predefined metrics and benchmarks. This approach incentivizes executives to drive growth and maximize shareholder value."},{"section":"Insights into Governance","text":"The corporate governance practices of PaxMedica Inc demonstrate a commitment to transparency, accountability, and aligning the interests of executives with those of shareholders. The diverse board composition allows for independent oversight and brings a range of perspectives to decision-making. The performance-based executive compensation policy provides incentives for executives to deliver strong financial and strategic results. Overall, these governance practices contribute to effective leadership, risk management, and long-term value creation for the company and its shareholders."}],"tags":["CrossOver55","Long","Pharmaceuticals"],"news":[{"category":"company","date":1699367189,"headline":"Penny Stocks To Buy Now? 3 to Watch With Big News","id":123685169,"image":"https://pennystocks.com/wp-content/uploads/2022/10/biotech-penny-stocks-to-buy-list.jpg","symbol":"PXMD","publisher":"PennyStocks","summary":"Biotech penny stocks to watch this week.","url":"https://pennystocks.com/featured/2023/11/07/penny-stocks-to-buy-now-3-to-watch-with-big-news/"},{"category":"company","date":1699362000,"headline":"PaxMedica Announces Publication of Its Autism Spectrum Disorder Phase 2 Study Results in Peer-reviewed Journal","id":123689494,"image":"https://media.zenfs.com/en/accesswire.ca/bcc0680d1a8156db5029b25cc8e4a030","symbol":"PXMD","publisher":"Yahoo","summary":"TARRYTOWN, NY / ACCESSWIRE / November 7, 2023 / PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, announced the publication of research findings in the Annals of General Psychiatry. ...","url":"https://finance.yahoo.com/news/paxmedica-announces-publication-autism-spectrum-130000425.html"},{"category":"company","date":1699353900,"headline":"Why Is TransMedics (TMDX) Stock Up 53% Today?","id":123689030,"image":"","symbol":"PXMD","publisher":"InvestorPlace","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3199921781"},{"category":"company","date":1699352280,"headline":"Why Is PaxMedica (PXMD) Stock Up 95% Today?","id":123689031,"image":"","symbol":"PXMD","publisher":"InvestorPlace","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3199879345"},{"category":"company","date":1699351800,"headline":"PaxMedica Shares Triple After Positive Results for Possible Autism Treatment","id":123714021,"image":"https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png","symbol":"PXMD","publisher":"MarketWatch","summary":"By Chris Wack PaxMedica shares tripled to $8.52 after the company saw positive results from research exploring the potential of low-dose suramin for autism...","url":"https://www.marketwatch.com/story/paxmedica-shares-triple-after-positive-results-for-possible-autism-treatment-628b765f"},{"category":"company","date":1699347720,"headline":"Clover Health Investments, Augmedix among healthcare movers","id":123689032,"image":"","symbol":"PXMD","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3199757377"},{"category":"company","date":1699347120,"headline":"US Stocks Mixed; D.R. Horton Earnings Top Views","id":123689034,"image":"","symbol":"PXMD","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3199741706"},{"category":"company","date":1699343220,"headline":"PaxMedica announces publication of ASD Phase 2 study results","id":123689035,"image":"","symbol":"PXMD","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3199644173"},{"category":"company","date":1699270440,"headline":"12 Health Care Stocks Moving In Monday's Intraday Session","id":123665344,"image":"","symbol":"PXMD","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3197902968"},{"category":"company","date":1698928200,"headline":"PaxMedica Engages Bourne Partners to Explore Future Monetization of Potential Priority Review Voucher (PRV)","id":123593708,"image":"https://s.yimg.com/ny/api/res/1.2/xnJCZ2qnhKPErEBbWRRhfA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD0zNTM-/https://media.zenfs.com/en/globenewswire.com/959e3638d7c287b8356c83d9e4010bb7","symbol":"PXMD","publisher":"Yahoo","summary":"TARRYTOWN, N.Y., Nov. 02, 2023 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (Nasdaq: PXMD), a pioneering biopharmaceutical company focused on advancing treatments for neurologic disorders, has engaged Bourne Partners, a leading financial services firm specializing in the pharma, pharma services, and consumer health sectors. This marks an important step in PaxMedica's efforts to explore potential monetization of a Priority Review Voucher (PRV) prior to filing the NDA for PAX-101 for the treatme","url":"https://finance.yahoo.com/news/paxmedica-engages-bourne-partners-explore-123000967.html"},{"category":"company","date":1698910800,"headline":"PaxMedica has engaged Bourne Partners","id":123589806,"image":"","symbol":"PXMD","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3191184945"},{"category":"company","date":1698753600,"headline":"PaxMedica Acquires Suramin Research Assets from Rediscovery Life Sciences to Accelerate NDA   Submission for PAX-101","id":123521678,"image":"https://s.yimg.com/ny/api/res/1.2/xnJCZ2qnhKPErEBbWRRhfA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD0zNTM-/https://media.zenfs.com/en/globenewswire.com/959e3638d7c287b8356c83d9e4010bb7","symbol":"PXMD","publisher":"Yahoo","summary":"TARRYTOWN, New York, Oct. 31, 2023 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (Nasdaq: PXMD), a pioneering biopharmaceutical company specializing in cutting-edge treatments for neurological disorders, announced today the successful acquisition of certain suramin research assets from Rediscovery Life Sciences (RLS). These assets were previously dedicated to the study of suramin's potential efficacy in treating acute kidney injury resulting from chronic kidney disease. The newly acquired data","url":"https://finance.yahoo.com/news/paxmedica-acquires-suramin-research-assets-120000727.html"},{"category":"company","date":1698740940,"headline":"PaxMedica buys research assets to support PAX-101 FDA application","id":123528455,"image":"","symbol":"PXMD","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3186977688"},{"category":"company","date":1698736680,"headline":"PaxMedica acquires certain suramin research assets from RLS","id":123528457,"image":"","symbol":"PXMD","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3186882013"},{"category":"company","date":1698679800,"headline":"PaxMedica Announces 1-for-17 Reverse Stock Split","id":123506837,"image":"https://s.yimg.com/ny/api/res/1.2/xnJCZ2qnhKPErEBbWRRhfA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD0zNTM-/https://media.zenfs.com/en/globenewswire.com/959e3638d7c287b8356c83d9e4010bb7","symbol":"PXMD","publisher":"Yahoo","summary":"TARRYTOWN, N.Y. , Oct. 30, 2023 (GLOBE NEWSWIRE) -- via IBN — PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (APT) for the treatment of Autism Spectrum Disorder (ASD) and other serious conditions with intractable neurologic symptoms, today announced that as a result of its 1-for-17 reverse stock split of its common stock that became effective at 8:03 a.m. Eastern Time on October 30, 2023, its common s","url":"https://finance.yahoo.com/news/paxmedica-announces-1-17-reverse-153000633.html"},{"category":"company","date":1698647520,"headline":"Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday","id":123496979,"image":"","symbol":"PXMD","publisher":"InvestorPlace","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3184898005"},{"category":"company","date":1698410040,"headline":"12 Health Care Stocks Moving In Friday's Intraday Session","id":123455826,"image":"","symbol":"PXMD","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3181658214"},{"category":"company","date":1698394080,"headline":"12 Health Care Stocks Moving In Friday's Pre-Market Session","id":123452749,"image":"","symbol":"PXMD","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3181263174"},{"category":"company","date":1698342660,"headline":"PaxMedica's Research on Low Dose Suramin for Autism Spectrum Disorder Accepted for Publication","id":123427238,"image":"https://s.yimg.com/ny/api/res/1.2/xnJCZ2qnhKPErEBbWRRhfA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD0zNTM-/https://media.zenfs.com/en/globenewswire.com/959e3638d7c287b8356c83d9e4010bb7","symbol":"PXMD","publisher":"Yahoo","summary":"TARRYTOWN, N.Y. , Oct. 26, 2023 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (Nasdaq: PXMD) a clinical-stage biopharmaceutical company, is excited to announce that the Annals of General Psychiatry, an internationally recognized scientific psychiatry publication, has accepted the manuscript titled \"Randomized clinical trial of low dose suramin intravenous infusions for treatment of autism spectrum disorder\" for publication. This groundbreaking research, authored by PaxMedica’s Chief Medical Off","url":"https://finance.yahoo.com/news/paxmedicas-research-low-dose-suramin-175100557.html"},{"category":"company","date":1698324900,"headline":"PaxMedica says research on suramin for autism spectrum disorder to be published","id":123427190,"image":"","symbol":"PXMD","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3179583115"},{"category":"company","date":1698323700,"headline":"12 Health Care Stocks Moving In Thursday's Intraday Session","id":123422445,"image":"","symbol":"PXMD","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3179549407"},{"category":"company","date":1698323340,"headline":"Why Harley-Davidson Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session","id":123422446,"image":"","symbol":"PXMD","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3179537334"},{"category":"company","date":1698321600,"headline":"PaxMedica Holds Important FDA Type-B Meeting to Review PAX-101 Pivotal Trial Data","id":123422151,"image":"","symbol":"PXMD","publisher":"Yahoo","summary":"Key Guidance Regarding NDA Filing ObtainedTARRYTOWN, NY / ACCESSWIRE / October 26, 2023 / PaxMedica, Inc. (NASDAQ:PXMD), a clinical-stage biopharmaceutical company, announced the completion of a type-B meeting with the FDA. During the live meeting, ...","url":"https://finance.yahoo.com/news/paxmedica-holds-important-fda-type-120000554.html"},{"category":"company","date":1698312480,"headline":"PaxMedica stock soars 110% on FDA update for lead drug PAX-101","id":123427195,"image":"","symbol":"PXMD","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3179238148"},{"category":"company","date":1698310020,"headline":"US Stocks Mixed; Bristol Myers Posts Upbeat Earnings","id":123427196,"image":"","symbol":"PXMD","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3179176300"},{"category":"company","date":1698307860,"headline":"12 Health Care Stocks Moving In Thursday's Pre-Market Session","id":123420445,"image":"","symbol":"PXMD","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3179119790"},{"category":"company","date":1698304920,"headline":"PaxMedica completes Type-B meeting with FDA for PAX-101 trial data","id":123427198,"image":"","symbol":"PXMD","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3179051595"},{"category":"company","date":1698284760,"headline":"Why Is PaxMedica (PXMD) Stock Up Today?","id":123427200,"image":"","symbol":"PXMD","publisher":"InvestorPlace","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3179672837"}]}